ROMAN PEREZ-SOLER, MD
Osteopathic Medicine at 210 St, Bronx, NY

2010005, Mar 4, 2010

Aug 24, 2009

12/583642

Yiyu Zou - Bronx NY, US
Roman Perez-Soler - New York NY, US

A61K 9/12, A61K 31/706, A61P 35/00

424 45, 514 43

The present invention is directed to methods for treating bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to methods for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for treating bronchial premalignancy and/or lung cancer in a subject comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier.

6437105, Aug 20, 2002

Nov 2, 1999

09/432190

Waldemar Priebe - Houston TX
Teresa Przewloka - Acton MA
Izabela Fokt - The Woodlands TX
Yi-He Ling - New York NY
Roman Perez-Soler - New York NY

Board of Regents, The University of Texas System - Austin TX

C07H 1524

536 64

The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-based DNA alkylators.

6355784, Mar 12, 2002

Jun 10, 1999

09/330226

Waldemar Priebe - Houston TX 77005
Marta Krawczyk - Lexington KY 40503
Piotr Skibicki - Warsaw 04015, PL
Izabela Fokt - The Woodlands TX 77380
Krzysztof Dziewiszek - The Woodlands TX 77380
Grzegorz Grynkiewicz - 05-092 Lomianki, PL
Roman Perez-Soler - New York NY 10016

C07H 1524

536 64, 536 41, 536 172, 536 184, 536 187, 536122

The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In doxorubicin (DOX) sensitive cell lines, they are at least as cytotoxic as DOX and in some cases more so. Many of these 4′- and 6′-fluorinated anthracyclines are more effective against multidrug-resistant tumors than was DOX, and/or have greater effectiveness than DOX against DOX sensitive cells. The compounds of this invention also have anti-amyloidogenic effects and the use of these compounds in the treatment of Alzheimers disease is contemplated.

7157098, Jan 2, 2007

Jan 6, 1999

09/225699

Roman Perez-Soler - New York NY, US
Yiyu Zou - Houston TX, US

A61K 51/00, A61K 9/127, C12N 15/88

424450, 424 121, 435458

The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.

2006016, Jul 27, 2006

Apr 5, 2006

11/398243

Roman Perez-Soler - New York NY, US
Yiyu Zou - Houston TX, US

A61K 48/00, A61K 9/127

424450000, 514044000, 977907000

The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.

2007019, Aug 16, 2007

Nov 3, 2006

11/592714

Frank Pilkiewicz - Princeton NJ, US
Roman Perez-Soler - New York NY, US
Walter Perkins - Pennington NJ, US
Yiyu Zou - Bronx NY, US
Mary Neville - Jamesburg NJ, US
Jin Lee - Belle Mead NJ, US

A61K 33/24, A61K 31/555, A61K 31/282

424649000, 514184000, 514492000

In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation wherein the concentration of the platinum compound of the lipid-based platinum compound formulation is greater than about 1.2 mg/ml.

7557090, Jul 7, 2009

Aug 1, 2006

11/496976

Waldemar Priebe - Houston TX, US
Izabella Fokt - The Woodlands TX, US
Teresa Prezewloka - Acton MA, US
Marta Krawczyk - Greenfield WI, US
Piotr Skibicki - Warsaw, PL
Grzegorz Grynkiewicz - Lominaki, PL
Roman Perez-Soler - New York NY, US

Houston Pharmaceuticals, Inc. - Houston TX

A61K 31/70

514 34

The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.

2006024, Nov 2, 2006

Nov 8, 2005

11/269163

Frank Pilkiewicz - Princeton NJ, US
Roman Perez-Soler - New York NY, US
Yiyu Zou - Bronx NY, US
Kristen Pilkiewicz - , US

A61K 33/24, A61K 31/282, A61K 9/127

424450000, 424649000, 514492000

The present invention relates to a method of treating cancer in a patient comprising administering to the patient intraperitoneally, a cancer treating effective amount of a lipid-based platinum compound formulation.